Recombinant Canine IL-13 Protein

• Reactivity: Ca
• Applications: Bioactivity

Recombinant Canine IL-13 Protein Summary

• Details of Functionality: Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323. The ED 50 for this effect is 0.75-3.75 ng/mL.
• Source: E. coli-derived canine IL-13 protein Ser19-Arg131, with an N-terminal Met
• Accession #: Q9N0W9
• N-terminal Sequence: Met
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 12.5 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 10 kDa and 11 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 3 months, -20 to -70 degreesC under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 100 μg/mL in PBS containing at least 0.1% human or bovine serum albumin.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Canine IL-13 Protein

• ALRHMGC116789
• BHR1interleukin-13
• IL13
• IL-13
• IL-13MGC116788
• interleukin 13
• MGC116786
• NC30
• P600

Background

Interleukin-13 (IL-13) is a 17 kDa immunoregulatory cytokine that plays a key role in the pathogenesis of allergic asthma and atopy. It is secreted by Th1 and Th2 CD4 + T cells, NK cells, visceral smooth muscle cells, eosinophils, mast cells, and basophils (1 - 3). IL-13 circulates as a monomer with two internal disulfide bonds that contribute to a bundled four alpha -helix configuration (4, 5). Mature canine IL-13 shares 69%, 56%, and 55% amino acid sequence identity with human, mouse, and rat IL-13, respectively. Despite the low homology, it exhibits cross-species activity between human, mouse, and rat (6, 7). IL-13 has diverse activities on numerous cell types (8). On macrophages, IL-13 suppresses the production of proinflammatory cytokines and other cytotoxic substances. On B cells, IL-13 induces immunoglobulin class switching to IgE, upregulates the expression of MHC class II, CD71, CD72, and CD23, and costimulates proliferation. IL-13 upregulates IL-6 while downregulating IL-1 and TNF-alpha production by fibroblasts and endothelial cells. IL-13 binds with low affinity to IL-13 R alpha 1, triggering IL-13 R alpha 1 association with IL-4 R alpha . This high affinity receptor complex also functions as the type 2 IL-4 receptor complex (9, 10). Additionally, IL-13 binds with high affinity to IL-13 R alpha 2 which is expressed intracellularly, on the cell surface, and as a soluble molecule (11 - 14). IL-13 R alpha 2 regulates the bioavailability of both IL-13 and IL-4 and is overexpressed in glioma and several bronchial pathologies (10, 15, 16). Compared to wild type IL-13, the atopy-associated R110Q variant of IL-13 elicits increased responsiveness from eosinophils that express low levels of IL-13 R alpha 2 (17).

1. Wills-Karp, M. (2004) Immunol. Rev. 202:175.
2. Nakajima H. and K. Takatsu (2007) Int. Arch. Allergy Immunol. 142:265.
3. Yang, S. et al. (2000) J. Interferon Cytokine Res. 20:779.
4. Moy, F.J. et al. (2001) J. Mol. Biol. 310:219.
5. Eisenmesser, E.Z. et al. (2001) J. Mol. Biol. 310:231.
6. Ruetten, H. and C. Thiemermann (1997) Shock 8:409.
7. Lakkis, F.G. et al. (1997) Biochem. Biophys. Res. Commun. 235:529.
8. Wynn, T.A. (2003) Annu. Rev. Immunol. 21:425.
9. Andrews, A.L. et al. (2002) J. Biol. Chem. 277:46073.
10. Tabata, Y. et al. (2007) Curr. Allergy Asthma Rep. 7:338.
11. Chiaramonte, M.G. et al. (2003) J. Exp. Med. 197:687.
12. Daines, M.O. and G.K. Hershey (2002) J. Biol. Chem. 227:10387.
13. Matsumura, M. et al. (2007) Biochem. Biophys. Res. Commun. 360:464.
14. Tabata, Y. et al. (2007) J. Immunol. 177:7905.
15. Andrews, A.L. et al. (2006) J. Allergy Clin. Immunol. 118:858.
16. Joshi, B.H. et al. (2006) Vitam. Horm. 74:479.
17. Andrews, A. L. et al. (2007) J. Allergy Clin. Immunol. 120:91.

Publications for IL-13 (5894-CL)(2)

Publications using 5894-CL

• Jung, K;Ku, JY;Kwon, JS;Won, G;Yoon, H;Oh, SI;Kim, MH;Kim, C;Yoon, JS; IFN-?/TNF-? Synergism Induces Pro-Inflammatory Cytokine and Chemokine Production by In Vitro Canine Keratinocytes Veterinary sciences 2025-01-14 [PMID: 39852930] (Bioassay, Canine)
• T Mineshige, J Kamiie, G Sugahara, K Shirota A study on periostin involvement in the pathophysiology of canine atopic skin J. Vet. Med. Sci., 2017-11-27;0(0):. 2017-11-27 [PMID: 29176263] (Bioassay, Canine)

Bioinformatics

• Uniprot:
  • Q9N0W9()